Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CRLX101

Known as: Cyclodextrin-Based Polymer-Camptothecin CRLX101 
A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Nanoparticle-based therapeutics are being used to treat patients with solid tumors. Whereas nanoparticles have been shown to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
VEGF pathway-targeting antiangiogenic drugs, such as bevacizumab, when combined with chemotherapy have changed clinical practice… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Malignant gliomas are difficult to treat in clinical practice. This study was aimed to investigate the preclinical efficacy of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2016
Review
2016
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development… Expand
  • table I
Is this relevant?
2015
2015
PURPOSE Increased tumor hypoxia and hence elevated hypoxia-inducible factor-1α (HIF1α) is thought to limit the efficacy of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer molecule and camptothecin. The CRLX101 nanoparticle is… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
SummaryPatients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 5
  • figure 5
Is this relevant?
2012
2012
UNLABELLED Camptothecin showed remarkable anticancer activity in animal models of cancer but was restricted in clinical use for… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Camptothecin (CPT) is a potent broad-spectrum anticancer agent that acts through inhibition of topoisomerase 1. Clinical… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • table 1
Is this relevant?
2011
2011
CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by… Expand
  • table 1
  • table 2
  • table 4
  • table 3
Is this relevant?